INmune Bio (INMB) Q4 2025 Earnings Transcript

INmune Bio reported a $45.9 million net loss in 2025, up from $42.1 million, while R&D spending fell to $20.7 million from $33.2 million and G&A rose to $10.3 million. The company booked a $16.5 million impairment after XPro’s Phase II Alzheimer's trial missed its endpoint, but management said FDA alignment supports a Phase III path and cash of $24.8 million should fund operations through Q1 2027. CORDStrom remains the near-term catalyst, with U.K. MAA filing targeted for mid-summer 2026 and U.S./EMA filings later in the year.

Analysis

The market is likely underappreciating the asymmetry in INMB’s setup: this is no longer a single-binary R&D story, but a staged regulatory optionality stack with three independent readouts over the next 6-12 months. The most important second-order effect is that a credible CORDStrom filing sequence can re-rate the company on “regulatory execution” rather than “clinical speculation,” which tends to compress cost of capital and improves partnering leverage across the platform.

The Alzheimer’s franchise is weaker scientifically than management wants the market to believe, but the real investable point is different: FDA alignment gives XPro a financing bridge, not a full de-risking. That means the stock can drift higher on partnership headlines even if the program remains fundamentally shaky, but any delay in converting FDA alignment into a funded Phase III path will snap the multiple back quickly because the program is still consuming scarce capital with no near-term commercial offset.

CORDStrom is the cleaner catalyst, and the manufacturing consistency detail matters more than the headline endpoint language. For cell therapy names, CMC readiness often becomes the gating variable for institutional credibility; if the company can clear U.K. and then U.S. submission steps without a manufacturing hold, the market may begin pricing a regulatory asset with platform expansion value rather than a niche rare-disease shot. The contrarian risk is that every additional geography raises the surface area for comparability questions, and one poorly managed CMC response can push timelines right when the company’s cash runway becomes more visible.

The most interesting dynamic is that INKMune gives management a fallback narrative: a non-Alzheimer’s, clinically positive asset that can be used to justify platform capital allocation and reduce the “all-or-nothing” overhang. That said, the financing math still dominates the equity because runway only extends into Q1 2027; any stumble on CORDStrom timing or XPro partnering could force dilution before the first real regulatory value inflection.

Key Decisions for Investors

• Long INMB into the next 4-8 weeks only as a catalyst trade, not a core position; target upside is a step-up on CORDStrom filing confirmation and/or XPro partnership news, but size assuming 20-30% downside if timelines slip.
• If long INMB, hedge with a small short INMB call spread or buy puts expiring after the expected U.K. MAA window to protect against a manufacturing/CMC delay.
• For higher-conviction expression, pair long INMB against a basket short of pre-revenue neuro/rare-disease peers with weaker regulatory visibility; this isolates execution alpha if CORDStrom filing momentum continues.
• Do not add aggressively on any XPro partnership headline alone; wait for funded Phase III structure or an explicit transaction, since FDA alignment without capital is not a de-risking event.
• If INMB rallies sharply on regulatory optimism before filings are accepted, trim into strength; the stock likely trades the calendar, and missing one milestone can quickly unwind 15-25% of upside.